Giredestrant Plus Everolimus Demonstrates Promise in HR-Positive, HER2-Negative Breast Cancer
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses primary results from the phase 3 AVERA study evaluating giredestrant plus everolimus versus standard-of-care endocrine therapy plus everolimus in patients with metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer previously treated with a CDK4/6 inhibitor.
This combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in both the ESR1-mutant and overall populations, with a well-tolerated safety profile.
These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Source:
Mayer E, Tolaney SM, Martin M, et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA16
